Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Eckard Wimmer
State University New York Stony Brook, Department: Genetics
Should you be removed from our database? Contact us at [email protected]. Read more below.
Codagenix
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Wimmer is the founder of Codagenix and holds an equity interest. Codagenix is a company that commercializes vaccines and Dr. Wimmer's research is on vaccines.
Tailoring virulence of dengue virus in mammals and mosquitoes
Human infections by dengue viruses are a rapidly growing global health concern, with 2.5 billion people at risk, 100,000,000 annual infections, and tens of thousands of deaths. The studies outlined in this grant deal with basic issues of dengue virus genetics (encoding of specific viral proteins) and gene expression. Because we will construct dengue virus variants that have large segments of their genome recoded with a 'non-human design' but unchanged 'insect design' we propose to study the replication of the dengue variants also in its natural host and vector, Aedes aegypti. Since the basic strategy of computer-designed recoding allows us tailoring the virulence of the agent by specifically down-regulating the expression of virus-encoded proteins, our project offers a variety of possibilities to study replication phenotypes of dengue virus in tissue culture cells and experimental animals. There are no vaccines licensed that protect humans from dengue virus infection. Ultimately, we believe that our work proposed here will lead to a new class of unique vaccines that will prevent infection with, and disease caused by, all four dengue virus serotypes.
Filed on July 15, 2015.
Tell us what you know about Eckard Wimmer's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Eckard Wimmer”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Eckard Wimmer | State University New York Stony Brook | Conflict of Interest | Codagenix | Value cannot be readily determined |
| Eckard Wimmer | State University New York Stony Brook | Conflict of Interest | Lyse Bio | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.